Document is current
Any future updates will be listed below
-
Authors
Almeida, Marcio A.
Diego, Vincent P.
Viel, Kevin R.
Luu, Bernadette W.
Haack, Karin
Raja, Rajalingam
Ameri, Afshin
Chitlur, Meera
Rydz, Natalia
Lillicrap, David
Watts, Raymond G.
Kessler, Craig M.
Ramsey, Christopher
Dinh, Long V.
Kim, Benjamin
Powell, Jerry S.
Manusov, Eron G.
Peralta, Juan M.
Bouls, Ruayda
Abraham, Shirley M.
Shen, Yu-Min
Murillo, Carlos M.
Mead, Henry
Lehmann, Paul V.
Fine, Eli J.
Escobar, Miguel A.
Kumar, Satish
Konkle, Barbara A.
Williams-Blangero, Sarah
Kasper, Carol K.
Almasy, Laura
Cole, Shelley A.
Blangero, John https://orcid.org/0000-0001-6250-5723
Howard, Tom E. https://orcid.org/0000-0002-4550-278X
- License Information
-
More Information
Article History
Received: 19 September 2023
Revised: 11 February 2025
Accepted: 12 March 2025
First Online: 22 April 2025
Competing interests
: There are NO relevant conflicts for any co-author. BWL, LVD, JSP, and TEH are respectively the Director of Technical Operations, Director of Drug Discovery, Chief Medical Officer and Chief Scientific Officer of Haplogenics Corporation. Dr. Henry Mead was an employee of BioMarin and is currently a consultant for Haplogenics Corporation. Dr. Paul Lehmann is the Co-Founder, President and CEO of Cellular Technology Limited.
: All methods used in the PATH study were performed in accordance with the relevant guidelines and regulations. All human subjects research components of the PATH study were approved by the IRB Committees at the Los Angeles Veterans Affairs Medical Center (IRB: 2009-091280) and Bloodworks Northwest (IRB: 13018). All participants in the PATH study gave informed consent.
